<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Cardiology1861-06841861-0692Springer Berlin HeidelbergBerlin/Heidelberg pmcid: 72524211656 doi: 10.1007/s00392-020-01656-3 : Review Coronavirus" exact="Disease" post="2019 (COVID-19) and its implications for cardiovascular care: expert"/>
 <result pre=": Review Coronavirus Disease 2019 (COVID-19) and its implications for" exact="cardiovascular" post="care: expert document from the German Cardiac Society and"/>
 <result pre="its implications for cardiovascular care: expert document from the German" exact="Cardiac" post="Society and the World Heart Federation BÃ¶hmMichaelmichael.boehm@uks.eu1FreyNorbert2GiannitsisEvangelos3SliwaKaren4ZeiherAndreas M.5[1], grid.411937.9Klinik"/>
 <result pre="expert document from the German Cardiac Society and the World" exact="Heart" post="Federation BÃ¶hmMichaelmichael.boehm@uks.eu1FreyNorbert2GiannitsisEvangelos3SliwaKaren4ZeiherAndreas M.5[1], grid.411937.9Klinik fÃ¼r Innere Medizin III, Kardiologie,"/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="affecting people at high risk and particularly at advanced age," exact="cardiovascular" post="and pulmonary disease. As cardiovascular patients are at high"/>
 <result pre="at high risk and particularly at advanced age, cardiovascular and" exact="pulmonary" post="disease. As cardiovascular patients are at high risk but"/>
 <result pre="and particularly at advanced age, cardiovascular and pulmonary disease. As" exact="cardiovascular" post="patients are at high risk but also have dyspnea"/>
 <result pre="those with or without COVID-19 but most importantly when comorbid" exact="cardiovascular" post="conditions are present. Severe COVID-19 with acute respiratory distress"/>
 <result pre="COVID-19 but most importantly when comorbid cardiovascular conditions are present." exact="Severe" post="COVID-19 with acute respiratory distress (ARDS) is challenging as"/>
 <result pre="importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with" exact="acute" post="respiratory distress (ARDS) is challenging as patients with elevated"/>
 <result pre="when comorbid cardiovascular conditions are present. Severe COVID-19 with acute" exact="respiratory" post="distress (ARDS) is challenging as patients with elevated myocardial"/>
 <result pre="outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the" exact="viral" post="receptor for cell entry and as the Coronavirus is"/>
 <result pre="and as the Coronavirus is downregulating this enzyme, which provides" exact="cardiovascular" post="and pulmonary protection, there is ongoing discussions on whether"/>
 <result pre="the Coronavirus is downregulating this enzyme, which provides cardiovascular and" exact="pulmonary" post="protection, there is ongoing discussions on whether treatment with"/>
 <result pre="pulmonary protection, there is ongoing discussions on whether treatment with" exact="cardiovascular" post="drugs, which upregulate the viral receptor ACE2 should be"/>
 <result pre="discussions on whether treatment with cardiovascular drugs, which upregulate the" exact="viral" post="receptor ACE2 should be modified. As most of the"/>
 <result pre="should be modified. As most of the COVID-19 patients have" exact="cardiovascular" post="comorbidities like hypertension, diabetes, coronary artery disease and heart"/>
 <result pre="of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes," exact="coronary artery disease" post="and heart failure, which imposes a high risk on"/>
 <result pre="the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary" exact="artery disease" post="and heart failure, which imposes a high risk on"/>
 <result pre="COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery" exact="disease" post="and heart failure, which imposes a high risk on"/>
 <result pre="patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease" exact="and heart" post="failure, which imposes a high risk on these patients,"/>
 <result pre="have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and" exact="heart" post="failure, which imposes a high risk on these patients,"/>
 <result pre="heart failure, which imposes a high risk on these patients," exact="cardiovascular" post="therapy should not be modified or even withdrawn. As"/>
 <result pre="with poor outcomes, swift diagnostic management and specialist care of" exact="cardiovascular" post="patients in the area of COVID-19 is of particular"/>
 <result pre="of particular importance and deserves special attention. Keywords CORONA COVID-19" exact="Heart" post="failure Hypertension Cardiovascular risk Myocardial injury COVID-19 and cardiovascular"/>
 <result pre="importance and deserves special attention. Keywords CORONA COVID-19 Heart failure" exact="Hypertension" post="Cardiovascular risk Myocardial injury COVID-19 and cardiovascular care After"/>
 <result pre="COVID-19 Heart failure Hypertension Cardiovascular risk Myocardial injury COVID-19 and" exact="cardiovascular" post="care After the first cases of respiratory illness were"/>
 <result pre="injury COVID-19 and cardiovascular care After the first cases of" exact="respiratory" post="illness were reported in December 2019, a novel coronavirus,"/>
 <result pre="reported in December 2019, a novel coronavirus, designated as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified to cause"/>
 <result pre="in December 2019, a novel coronavirus, designated as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), was identified to cause the"/>
 <result pre="December 2019, a novel coronavirus, designated as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), was identified to cause the so-called"/>
 <result pre="coronavirus 2 (SARS-CoV-2), was identified to cause the so-called coronavirus" exact="disease" post="(COVID-19), which meanwhile has become a worldwide pandemic [1,"/>
 <result pre="general, three distinct phases characterize progression of COVID-19: an initial" exact="infection" post="phase followed by a respiratory distress phase and finally"/>
 <result pre="progression of COVID-19: an initial infection phase followed by a" exact="respiratory" post="distress phase and finally culminating in a severe hyperinflammation"/>
 <result pre="a severe hyperinflammation state with more than 80% of SARS-CoV-2" exact="infections" post="showing only mild or even absent symptoms [3]. The"/>
 <result pre="reported from China [3] provided important lessons with respect to" exact="cardiovascular" post="involvements both as a primary target as well as"/>
 <result pre="important lessons with respect to cardiovascular involvements both as a" exact="primary" post="target as well as a comorbidity. The infection phase"/>
 <result pre="as a primary target as well as a comorbidity. The" exact="infection" post="phase marks virus infiltration and proliferation of the epithelium"/>
 <result pre="the epithelium and lung parenchyma accompanied by mild symptoms and" exact="monocyte" post="/ macrophage activation as the initial immune response. The"/>
 <result pre="processes like vasodilation, endothelial leakiness and leukocyte extravasation lead to" exact="pulmonary" post="distress with pulmonary damage, fluid extravasation and hypoxemia, which"/>
 <result pre="endothelial leakiness and leukocyte extravasation lead to pulmonary distress with" exact="pulmonary" post="damage, fluid extravasation and hypoxemia, which in turn augments"/>
 <result pre="pulmonary damage, fluid extravasation and hypoxemia, which in turn augments" exact="cardiovascular" post="stress. Finally, further amplification of the host inflammatory response"/>
 <result pre="amplification of the host inflammatory response will essentially culminate in" exact="systemic" post="inflammation up to eliciting a cytokine storm [4]. Importantly,"/>
 <result pre="inflammation up to eliciting a cytokine storm [4]. Importantly, the" exact="cardiovascular" post="system emerges as both a primary target as well"/>
 <result pre="storm [4]. Importantly, the cardiovascular system emerges as both a" exact="primary" post="target as well as the most important secondary co-morbidity"/>
 <result pre="both a primary target as well as the most important" exact="secondary" post="co-morbidity factor during all three of the COVID-19 progression"/>
 <result pre="progression phases (Fig.Â 1). There is accumulating evidence that the" exact="heart" post="itself might be a direct target for viral infection"/>
 <result pre="that the heart itself might be a direct target for" exact="viral infection" post="with SARS-CoV-2 [5]. Previous studies examining the cardiovascular effects"/>
 <result pre="the heart itself might be a direct target for viral" exact="infection" post="with SARS-CoV-2 [5]. Previous studies examining the cardiovascular effects"/>
 <result pre="for viral infection with SARS-CoV-2 [5]. Previous studies examining the" exact="cardiovascular" post="effects of viral respiratory infections during influenza epidemics revealed"/>
 <result pre="with SARS-CoV-2 [5]. Previous studies examining the cardiovascular effects of" exact="viral" post="respiratory infections during influenza epidemics revealed a profound up"/>
 <result pre="SARS-CoV-2 [5]. Previous studies examining the cardiovascular effects of viral" exact="respiratory" post="infections during influenza epidemics revealed a profound up to"/>
 <result pre="[5]. Previous studies examining the cardiovascular effects of viral respiratory" exact="infections" post="during influenza epidemics revealed a profound up to sixfold"/>
 <result pre="revealed a profound up to sixfold increased incidence ratio for" exact="acute" post="myocardial infarction within 7Â days of infection, in part"/>
 <result pre="a profound up to sixfold increased incidence ratio for acute" exact="myocardial infarction" post="within 7Â days of infection, in part due to"/>
 <result pre="the heightened prothrombotic activity leading to intracoronary thrombotic events [6]." exact="Hypotension" post="and tachycardia will further imbalance the metabolic demand of"/>
 <result pre="further imbalance the metabolic demand of a diseased heart. Exaggerated" exact="systemic" post="inflammation with profoundly increased circulating levels of prototypical inflammatory"/>
 <result pre="with a profoundly worse clinical outcome [9, 10]. Myocardial damage" exact="and heart" post="failure contributed to almost 40% of deaths in a"/>
 <result pre="a profoundly worse clinical outcome [9, 10]. Myocardial damage and" exact="heart" post="failure contributed to almost 40% of deaths in a"/>
 <result pre="Cox regression analyses revealed that the mortality risk associated with" exact="acute" post="cardiac damage was significantly higher than age, chronic pulmonary"/>
 <result pre="associated with acute cardiac damage was significantly higher than age," exact="chronic" post="pulmonary disease or prior history of cardiovascular disease [8,"/>
 <result pre="with acute cardiac damage was significantly higher than age, chronic" exact="pulmonary" post="disease or prior history of cardiovascular disease [8, 9]."/>
 <result pre="acute cardiac damage was significantly higher than age, chronic pulmonary" exact="disease" post="or prior history of cardiovascular disease [8, 9]. Thus,"/>
 <result pre="higher than age, chronic pulmonary disease or prior history of" exact="cardiovascular disease" post="[8, 9]. Thus, both direct and indirect mechanisms of"/>
 <result pre="than age, chronic pulmonary disease or prior history of cardiovascular" exact="disease" post="[8, 9]. Thus, both direct and indirect mechanisms of"/>
 <result pre="disease [8, 9]. Thus, both direct and indirect mechanisms of" exact="cardiovascular" post="injury most likely play a pivotal role for the"/>
 <result pre="play a pivotal role for the deleterious consequences of SARS-CoV-2" exact="infection" post="in addition to the severe acute respiratory distress syndrome"/>
 <result pre="deleterious consequences of SARS-CoV-2 infection in addition to the severe" exact="acute" post="respiratory distress syndrome (ARDS). Fig. 1 Summary of consequences"/>
 <result pre="consequences of SARS-CoV-2 infection in addition to the severe acute" exact="respiratory" post="distress syndrome (ARDS). Fig. 1 Summary of consequences of"/>
 <result pre="SARS-CoV-2 infection in addition to the severe acute respiratory distress" exact="syndrome" post="(ARDS). Fig. 1 Summary of consequences of SARS-Cov2 infection"/>
 <result pre="distress syndrome (ARDS). Fig. 1 Summary of consequences of SARS-Cov2" exact="infection" post="on the cardiovascular system summarizing primary targets (left) and"/>
 <result pre="Fig. 1 Summary of consequences of SARS-Cov2 infection on the" exact="cardiovascular" post="system summarizing primary targets (left) and secondary comorbidities (right)"/>
 <result pre="of consequences of SARS-Cov2 infection on the cardiovascular system summarizing" exact="primary" post="targets (left) and secondary comorbidities (right) Last, patients with"/>
 <result pre="infection on the cardiovascular system summarizing primary targets (left) and" exact="secondary" post="comorbidities (right) Last, patients with underlying cardiovascular disease are"/>
 <result pre="targets (left) and secondary comorbidities (right) Last, patients with underlying" exact="cardiovascular disease" post="are more likely to be infected with SARS-CoV-2, are"/>
 <result pre="(left) and secondary comorbidities (right) Last, patients with underlying cardiovascular" exact="disease" post="are more likely to be infected with SARS-CoV-2, are"/>
 <result pre="COVID-19 patients in Germany disclosed that in all classes of" exact="disease" post="severity more than 50% of the patients suffered from"/>
 <result pre="disease severity more than 50% of the patients suffered from" exact="cardiovascular" post="co-morbidity, which was by far the most prominent co-morbidity"/>
 <result pre="Fig. 2 Distribution of comorbidities in different intensities of COVID-19" exact="infections" post="Taken together, cardiovascular involvement is both highly prevalent and"/>
 <result pre="of comorbidities in different intensities of COVID-19 infections Taken together," exact="cardiovascular" post="involvement is both highly prevalent and of significant prognostic"/>
 <result pre="is not only important to fully involve cardiologists for managing" exact="cardiovascular" post="complications in severe cases of COVID-19, but also to"/>
 <result pre="cases of COVID-19, but also to pay particular attention to" exact="cardiovascular" post="protection of patients at risk to develop COVID-19. It"/>
 <result pre="COVID-19. It will be essential to allocate sufficient resources for" exact="cardiovascular" post="diagnostic and therapeutic procedures, even at times when the"/>
 <result pre="hospitals are guided by measures to contain and treat this" exact="infectious disease." post="We need to advice patients that cardiovascular emergencies like"/>
 <result pre="treat this infectious disease. We need to advice patients that" exact="cardiovascular" post="emergencies like STEMI, decompensated heart failure or life-threatening arrhythmias"/>
 <result pre="need to advice patients that cardiovascular emergencies like STEMI, decompensated" exact="heart" post="failure or life-threatening arrhythmias need immediate attention and treatment"/>
 <result pre="COVID-19 patients are guided by clinical necessity. Fortunately, all major" exact="cardiovascular" post="professional societies are meanwhile in the process of publishing"/>
 <result pre="in the process of publishing guidance for various aspects of" exact="cardiovascular" post="care in COVID-19 patients, including how and in whom"/>
 <result pre="without any doubt lead to greater awareness of the immediate" exact="cardiovascular" post="implications of this infectious disease. Nevertheless, we should not"/>
 <result pre="to greater awareness of the immediate cardiovascular implications of this" exact="infectious disease." post="Nevertheless, we should not stop here. Hospitalization for pneumonia"/>
 <result pre="infectious disease. Nevertheless, we should not stop here. Hospitalization for" exact="pneumonia" post="was previously shown to be associated with a significantly"/>
 <result pre="shown to be associated with a significantly increased risk of" exact="cardiovascular disease" post="up to 10Â years of follow-up [13]. It is"/>
 <result pre="to be associated with a significantly increased risk of cardiovascular" exact="disease" post="up to 10Â years of follow-up [13]. It is"/>
 <result pre="years of follow-up [13]. It is very likely that SARS-CoV-2" exact="infections" post="with respiratory impairment will also lead to similar long-term"/>
 <result pre="follow-up [13]. It is very likely that SARS-CoV-2 infections with" exact="respiratory" post="impairment will also lead to similar long-term adverse events."/>
 <result pre="long-term consequences on cardiac function, including definite proof of SARS-CoV-2-induced" exact="myocarditis" post="by myocardial biopsy. Likewise, it will be important to"/>
 <result pre="to assess potential long-term cardiotoxic effects of antiviral therapy. Thus," exact="cardiovascular" post="care during the COVID-19 pandemic should already implement strategies"/>
 <result pre="of the world. Unexplained is the different impact of the" exact="disease" post="in different countries. There has been a slow increase"/>
 <result pre="in different countries. There has been a slow increase in" exact="infections" post="in Africa and South-East Asia with a surprisingly low"/>
 <result pre="low fatality rate. 14th April 2020 South Africa had 2272" exact="infections" post="with 27 deaths despite a detailed surveillance system (www.coronavirus.jhu.edu"/>
 <result pre="of many low-to-middle income countries is more than 2 decades" exact="lower" post="than in higher income countries. For example in Uganda"/>
 <result pre="than 60Â years. This age pyramid influences the current Uganda" exact="cardiovascular" post="health challenges which does include hypertension and coronary artery"/>
 <result pre="influences the current Uganda cardiovascular health challenges which does include" exact="hypertension" post="and coronary artery disease, mainly in urban areas, but"/>
 <result pre="current Uganda cardiovascular health challenges which does include hypertension and" exact="coronary artery disease," post="mainly in urban areas, but rheumatic heart disease (RHD)"/>
 <result pre="Uganda cardiovascular health challenges which does include hypertension and coronary" exact="artery disease," post="mainly in urban areas, but rheumatic heart disease (RHD)"/>
 <result pre="hypertension and coronary artery disease, mainly in urban areas, but" exact="rheumatic" post="heart disease (RHD) and heart failure due to cardiomyopathies"/>
 <result pre="and coronary artery disease, mainly in urban areas, but rheumatic" exact="heart" post="disease (RHD) and heart failure due to cardiomyopathies remain"/>
 <result pre="coronary artery disease, mainly in urban areas, but rheumatic heart" exact="disease" post="(RHD) and heart failure due to cardiomyopathies remain enormous"/>
 <result pre="disease, mainly in urban areas, but rheumatic heart disease (RHD)" exact="and heart" post="failure due to cardiomyopathies remain enormous challenges. Most of"/>
 <result pre="mainly in urban areas, but rheumatic heart disease (RHD) and" exact="heart" post="failure due to cardiomyopathies remain enormous challenges. Most of"/>
 <result pre="not have access to balloon valvotomy or surgery [14]. Untreated" exact="symptomatic" post="patients with rheumatic heart disease have a mortality rate"/>
 <result pre="to balloon valvotomy or surgery [14]. Untreated symptomatic patients with" exact="rheumatic" post="heart disease have a mortality rate of 20% per"/>
 <result pre="balloon valvotomy or surgery [14]. Untreated symptomatic patients with rheumatic" exact="heart" post="disease have a mortality rate of 20% per annum"/>
 <result pre="valvotomy or surgery [14]. Untreated symptomatic patients with rheumatic heart" exact="disease" post="have a mortality rate of 20% per annum leaving"/>
 <result pre="mechanism could be the high number of people living with" exact="HIV/AIDS" post="on anti-retroviral therapy. South Africa has a population of"/>
 <result pre="2020 and 2021 or remain relatively spared [16]. The World" exact="Heart" post="Federation has published a briefing on prevention: Coronavirus Disease"/>
 <result pre="World Heart Federation has published a briefing on prevention: Coronavirus" exact="Disease" post="2019 in low-income countries [17]. This includes six easy"/>
 <result pre="From staying at home and avoiding large gathering to a" exact="total" post="shut down of a country had so far the"/>
 <result pre="a country had so far the biggest impact in a" exact="lower" post="number of infections and early case detection. Hypertension The"/>
 <result pre="so far the biggest impact in a lower number of" exact="infections" post="and early case detection. Hypertension The role of the"/>
 <result pre="in a lower number of infections and early case detection." exact="Hypertension" post="The role of the reninâ€&quot;angiotensinâ€&quot;aldosterone system in COVID-19 The"/>
 <result pre="system (RAAS) regulates blood pressure and is also involved in" exact="cardiovascular" post="endorgan damage like myocardial hypertrophy, interstitial myocardial fibrosis, atherosclerosis"/>
 <result pre="in cardiovascular endorgan damage like myocardial hypertrophy, interstitial myocardial fibrosis," exact="atherosclerosis" post="and plaque rupture in acute coronary syndromes. Therefore, blockers"/>
 <result pre="myocardial hypertrophy, interstitial myocardial fibrosis, atherosclerosis and plaque rupture in" exact="acute" post="coronary syndromes. Therefore, blockers of the RAAS are recommended"/>
 <result pre="blockers of the RAAS are recommended for the use in" exact="hypertension" post="to prevent cardiovascular events and heart failure [18, 19]."/>
 <result pre="RAAS are recommended for the use in hypertension to prevent" exact="cardiovascular" post="events and heart failure [18, 19]. The protease renin"/>
 <result pre="recommended for the use in hypertension to prevent cardiovascular events" exact="and heart" post="failure [18, 19]. The protease renin cleaves angiotensin to"/>
 <result pre="for the use in hypertension to prevent cardiovascular events and" exact="heart" post="failure [18, 19]. The protease renin cleaves angiotensin to"/>
 <result pre="(ACE) [20]. Angiotensin II stimulates AT1-receptors, which results in adverse" exact="cardiovascular" post="effects like vasoconstriction, cell proliferation and hypertrophy [21]. In"/>
 <result pre="results in adverse cardiovascular effects like vasoconstriction, cell proliferation and" exact="hypertrophy" post="[21]. In contrast, the AT2-receptor mediates vasodilation, anti-proliferative actions"/>
 <result pre="virus is internalized by clathrin-coated pits and, after trypsin cleavage," exact="viral" post="RNA is released into this cellular cytoplasm causing SARS"/>
 <result pre="viral RNA is released into this cellular cytoplasm causing SARS" exact="infection" post="[28, 29]. ACE2 is degraded and shedfrom the cell"/>
 <result pre="CORONA virus itself [31]. The role of ACE2 in CORONA" exact="virus infection" post="is scrutinized by the fact that several animals cannot"/>
 <result pre="virus itself [31]. The role of ACE2 in CORONA virus" exact="infection" post="is scrutinized by the fact that several animals cannot"/>
 <result pre="is a knockout of ACE2, which renders them resistant to" exact="infection" post="[32]. The role of ACE2 is not specific for"/>
 <result pre="the CORONA virus as ACE2 is also used by the" exact="respiratory" post="syncytial (RS) virus and some types of influenza viruses"/>
 <result pre="[33, 34]. ACE2 can also be regulated in several cardio-pulmonary" exact="disease" post="conditions like COPD, pulmonary hypertension, asthma and after viral"/>
 <result pre="also be regulated in several cardio-pulmonary disease conditions like COPD," exact="pulmonary" post="hypertension, asthma and after viral infections with influenza H1N1,"/>
 <result pre="regulated in several cardio-pulmonary disease conditions like COPD, pulmonary hypertension," exact="asthma" post="and after viral infections with influenza H1N1, H5N1, H7N9"/>
 <result pre="cardio-pulmonary disease conditions like COPD, pulmonary hypertension, asthma and after" exact="viral" post="infections with influenza H1N1, H5N1, H7N9 as well as"/>
 <result pre="disease conditions like COPD, pulmonary hypertension, asthma and after viral" exact="infections" post="with influenza H1N1, H5N1, H7N9 as well as in"/>
 <result pre="receptor [24], has been shown to improve lung injury after" exact="viral" post="infections of clinical injuries [36]. Furthermore, ARDS is not"/>
 <result pre="[24], has been shown to improve lung injury after viral" exact="infections" post="of clinical injuries [36]. Furthermore, ARDS is not prominent"/>
 <result pre="infectivity [25â€&quot;30]; however, it might also mediate beneficial effects on" exact="pulmonary" post="complications after infection [36, 37]. The fact that the"/>
 <result pre="it might also mediate beneficial effects on pulmonary complications after" exact="infection" post="[36, 37]. The fact that the major risk factor"/>
 <result pre="[38â€&quot;40] have been shown to upregulate ACE2 in the human" exact="heart" post="and in the systemic as well as pulmonary vasculature"/>
 <result pre="to upregulate ACE2 in the human heart and in the" exact="systemic" post="as well as pulmonary vasculature [40] with association to"/>
 <result pre="the human heart and in the systemic as well as" exact="pulmonary" post="vasculature [40] with association to outcomes in heart failure"/>
 <result pre="well as pulmonary vasculature [40] with association to outcomes in" exact="heart" post="failure [41], atrial fibrillation [42] and pulmonary hypertension [43]."/>
 <result pre="vasculature [40] with association to outcomes in heart failure [41]," exact="atrial fibrillation" post="[42] and pulmonary hypertension [43]. These findings highlight the"/>
 <result pre="[40] with association to outcomes in heart failure [41], atrial" exact="fibrillation" post="[42] and pulmonary hypertension [43]. These findings highlight the"/>
 <result pre="to outcomes in heart failure [41], atrial fibrillation [42] and" exact="pulmonary" post="hypertension [43]. These findings highlight the complex interaction of"/>
 <result pre="outcomes in heart failure [41], atrial fibrillation [42] and pulmonary" exact="hypertension" post="[43]. These findings highlight the complex interaction of COVID-19"/>
 <result pre="the CORONA virus and ACE2 into the cell where the" exact="viral" post="genome is released. The internalization as well as the"/>
 <result pre="membrane-bound ACE2. Furthermore, ACE2 is reduced by pathological conditions like" exact="pulmonary" post="fibrosis, asthma, COPD, pulmonary hypertension, smoking and old age"/>
 <result pre="is reduced by pathological conditions like pulmonary fibrosis, asthma, COPD," exact="pulmonary" post="hypertension, smoking and old age [17]. On the contrary,"/>
 <result pre="and potentially ibuprofen, and ACE2 is more abundantly expressed in" exact="childhood" post="and at young age. As ACE2 forms more Ang"/>
 <result pre="mediating anti-proliferative, anti-inflammatory action, hypothetically enhanced ACE2-expression might cause more" exact="infection" post="by acting as a receptor for viral cell entry"/>
 <result pre="might cause more infection by acting as a receptor for" exact="viral" post="cell entry and protect from pulmonary complications. In conditions"/>
 <result pre="as a receptor for viral cell entry and protect from" exact="pulmonary" post="complications. In conditions where is downregulation of ACE2, less"/>
 <result pre="pulmonary complications. In conditions where is downregulation of ACE2, less" exact="infection" post="might occur, but severity of COVID-19-related ARDS can be"/>
 <result pre="more severe. This hypothesis fits with the higher likelihood of" exact="pulmonary" post="complications in certain disease conditions and in aging. Notably,"/>
 <result pre="fits with the higher likelihood of pulmonary complications in certain" exact="disease" post="conditions and in aging. Notably, these data are derived"/>
 <result pre="studies and need to be scrutinized in clinical conditions Is" exact="hypertension" post="a risk factor for COVID-19? Arterial hypertension is the"/>
 <result pre="clinical conditions Is hypertension a risk factor for COVID-19? Arterial" exact="hypertension" post="is the most prevalent risk factor in cardiovascular disease,"/>
 <result pre="COVID-19? Arterial hypertension is the most prevalent risk factor in" exact="cardiovascular disease," post="in particular in China [44]. In several early trials"/>
 <result pre="in China [44]. In several early trials of COVID-19 populations," exact="hypertension" post="is the most prevalent cardiovascular risk factor and comorbidity"/>
 <result pre="early trials of COVID-19 populations, hypertension is the most prevalent" exact="cardiovascular" post="risk factor and comorbidity is amounting to approximately 30â€&quot;40%"/>
 <result pre="[47]. In those patients, who have complications or even died," exact="hypertension" post="is more prevalent as was diabetes, coronary artery disease,"/>
 <result pre="or even died, hypertension is more prevalent as was diabetes," exact="coronary artery disease," post="chronic obstructive lung disease or malignancies [9]. As hypertension"/>
 <result pre="even died, hypertension is more prevalent as was diabetes, coronary" exact="artery disease," post="chronic obstructive lung disease or malignancies [9]. As hypertension"/>
 <result pre="hypertension is more prevalent as was diabetes, coronary artery disease," exact="chronic" post="obstructive lung disease or malignancies [9]. As hypertension is"/>
 <result pre="is more prevalent as was diabetes, coronary artery disease, chronic" exact="obstructive lung disease" post="or malignancies [9]. As hypertension is the comorbidity with"/>
 <result pre="more prevalent as was diabetes, coronary artery disease, chronic obstructive" exact="lung disease" post="or malignancies [9]. As hypertension is the comorbidity with"/>
 <result pre="prevalent as was diabetes, coronary artery disease, chronic obstructive lung" exact="disease" post="or malignancies [9]. As hypertension is the comorbidity with"/>
 <result pre="artery disease, chronic obstructive lung disease or malignancies [9]. As" exact="hypertension" post="is the comorbidity with the highest prevalence in deceased"/>
 <result pre="if there is a deviation from the overall prevalence of" exact="hypertension" post="in the Chinese population. In China, the prevalence of"/>
 <result pre="hypertension in the Chinese population. In China, the prevalence of" exact="hypertension" post="is high. By comparing Chinese populations age-matched to those"/>
 <result pre="55â€&quot;74Â years), it becomes clear that the overall prevalence in" exact="hypertension" post="is 44% with a further increase in populations at"/>
 <result pre="at higher age [48]. Therefore, the prevalence of the comorbidity" exact="hypertension" post="in COVID-19 patients is lower and does not exceed"/>
 <result pre="the prevalence of the comorbidity hypertension in COVID-19 patients is" exact="lower" post="and does not exceed the overall prevalence in the"/>
 <result pre="relevant populations in China. Therefore, there is no evidence that" exact="hypertension" post="increases the likelihood to suffer from COVID-19. Cardiovascular risk"/>
 <result pre="patients who have fatal outcomes after COVID-19 [9]. Therefore, all" exact="cardiovascular" post="comorbidities in concert add to myocardial injury, which has"/>
 <result pre="differential outcome in COVID-19. The Guidelines for the Management of" exact="Hypertension" post="of the European Society of Cardiology [18], but also"/>
 <result pre="[18], but also Chinese guidelines [49] and Guidelines of the" exact="American" post="College of Cardiology (ACC) and American Heart Association (AHA)"/>
 <result pre="and Guidelines of the American College of Cardiology (ACC) and" exact="American" post="Heart Association (AHA) [19] recommend ACE and ARBs for"/>
 <result pre="Guidelines of the American College of Cardiology (ACC) and American" exact="Heart" post="Association (AHA) [19] recommend ACE and ARBs for the"/>
 <result pre="(AHA) [19] recommend ACE and ARBs for the treatment of" exact="hypertension" post="as these drugs have been shown to be effective"/>
 <result pre="as these drugs have been shown to be effective in" exact="secondary" post="prevention, heart failure and protection against adverse renal outcomes."/>
 <result pre="drugs have been shown to be effective in secondary prevention," exact="heart" post="failure and protection against adverse renal outcomes. In Germany,"/>
 <result pre="argue in favor or against the use of RAS-inhibitors in" exact="hypertension" post="as recently expressed in various short communications and letters"/>
 <result pre="use of RAS-inhibitors in hypertension as recently expressed in various" exact="short" post="communications and letters causing a lot of discussion and"/>
 <result pre="are necessary to scrutinize the definite role of ACE2 in" exact="infection" post="frequency and causation of pulmonary complications after CORONA infections."/>
 <result pre="definite role of ACE2 in infection frequency and causation of" exact="pulmonary" post="complications after CORONA infections. At this moment, there is"/>
 <result pre="thus no compelling evidentiary background to change RASi therapy for" exact="hypertension" post="or other cardiovascular conditions. COVID-19 and myocardial injury The"/>
 <result pre="evidentiary background to change RASi therapy for hypertension or other" exact="cardiovascular" post="conditions. COVID-19 and myocardial injury The cardiac manifestations of"/>
 <result pre="conditions. COVID-19 and myocardial injury The cardiac manifestations of SARS-CoV-2" exact="infection" post="include acute myocardial injury, heart failure, myocarditis, and ventricular"/>
 <result pre="and myocardial injury The cardiac manifestations of SARS-CoV-2 infection include" exact="acute" post="myocardial injury, heart failure, myocarditis, and ventricular tachyarrhythmias [59]."/>
 <result pre="The cardiac manifestations of SARS-CoV-2 infection include acute myocardial injury," exact="heart" post="failure, myocarditis, and ventricular tachyarrhythmias [59]. Along with ARDS,"/>
 <result pre="heart failure, myocarditis, and ventricular tachyarrhythmias [59]. Along with ARDS," exact="acute" post="myocardial injury was identified as an important independent predictor"/>
 <result pre="COVID-19 outbreak in Wuhan, China, reported very similar rates of" exact="acute" post="myocardial injury ranging between 7.2% [45], 12% [10], 17%"/>
 <result pre="unit (ICU) was significantly higher among patients with evidence of" exact="acute" post="myocardial injury (31% vs 4%). Several studies demonstrate an"/>
 <result pre="injury (31% vs 4%). Several studies demonstrate an association between" exact="acute" post="myocardial injury and mortality [7, 9]. In a study"/>
 <result pre="evaluated the role of hs-cTnT relative to the presence of" exact="cardiovascular disease" post="[8], mortality rates were highest among patients with elevated"/>
 <result pre="the role of hs-cTnT relative to the presence of cardiovascular" exact="disease" post="[8], mortality rates were highest among patients with elevated"/>
 <result pre="among patients with elevated hs-cTnT above ULN and history of" exact="cardiovascular disease" post="and lowest among those with normal hs-cTn, irrespective the"/>
 <result pre="patients with elevated hs-cTnT above ULN and history of cardiovascular" exact="disease" post="and lowest among those with normal hs-cTn, irrespective the"/>
 <result pre="lowest among those with normal hs-cTn, irrespective the presence or" exact="absence of" post="CV disease [8]. In a survey on 416 hospitalized"/>
 <result pre="those with normal hs-cTn, irrespective the presence or absence of" exact="CV disease" post="[8]. In a survey on 416 hospitalized patients in"/>
 <result pre="with normal hs-cTn, irrespective the presence or absence of CV" exact="disease" post="[8]. In a survey on 416 hospitalized patients in"/>
 <result pre="other imaging tests, except lung CT, at all. Hence, the" exact="limited" post="diagnostic workup and selection bias precludes any speculations on"/>
 <result pre="to the recommendations of the 4th version of the universal" exact="myocardial infarction" post="(MI) definition (UDMI) [61], the investigators of the Wuhan"/>
 <result pre="investigators of the Wuhan studies used a different definition for" exact="acute" post="myocardial injury and did not differentiate acute from chronic"/>
 <result pre="different definition for acute myocardial injury and did not differentiate" exact="acute" post="from chronic myocardial injury by a concentration change (â€œrise"/>
 <result pre="for acute myocardial injury and did not differentiate acute from" exact="chronic" post="myocardial injury by a concentration change (â€œrise and/or fallâ€�)"/>
 <result pre="injury by a concentration change (â€œrise and/or fallâ€�) of hs-cTnI." exact="Acute" post="myocardial injury was rather defined as blood levels of"/>
 <result pre="high sensitivity troponin T or I above the 99th percentile" exact="upper" post="limit of normal (upper limit of normal (ULN)â€‰&amp;gt;â€‰28Â ng/L),"/>
 <result pre="The investigators did not report on rates and subtypes of" exact="acute" post="myocardial infarction based on criteria of the 4th version"/>
 <result pre="investigators did not report on rates and subtypes of acute" exact="myocardial infarction" post="based on criteria of the 4th version of the"/>
 <result pre="whether monitoring of hs-cTn might be useful even in the" exact="absence of" post="a suspected acute coronary syndrome [7]. Overall, the presence"/>
 <result pre="might be useful even in the absence of a suspected" exact="acute" post="coronary syndrome [7]. Overall, the presence of myocardial injury"/>
 <result pre="useful even in the absence of a suspected acute coronary" exact="syndrome" post="[7]. Overall, the presence of myocardial injury in ED"/>
 <result pre="in as many as 20% of consecutive patients presenting with" exact="chest" post="pain, dyspnea, or less specific symptoms [62]. However, only"/>
 <result pre="only a fraction of elevations was ultimately attributed to a" exact="type 1" post="or type 2 MI and the majority of cases"/>
 <result pre="of elevations was ultimately attributed to a type 1 or" exact="type 2" post="MI and the majority of cases were unrelated to"/>
 <result pre="2 MI and the majority of cases were unrelated to" exact="myocardial ischemia," post="often multifactorial, or the exact reason remained unsettled [61]."/>
 <result pre="often multifactorial, or the exact reason remained unsettled [61]. In" exact="stable" post="or asymptomatic cardiovascular or ischemic heart disease, cardiac troponin"/>
 <result pre="the exact reason remained unsettled [61]. In stable or asymptomatic" exact="cardiovascular" post="or ischemic heart disease, cardiac troponin elevation may be"/>
 <result pre="reason remained unsettled [61]. In stable or asymptomatic cardiovascular or" exact="ischemic heart disease," post="cardiac troponin elevation may be explained by the presence"/>
 <result pre="remained unsettled [61]. In stable or asymptomatic cardiovascular or ischemic" exact="heart" post="disease, cardiac troponin elevation may be explained by the"/>
 <result pre="elevation may be explained by the presence of underlying structural" exact="heart" post="disease, stable CAD, and chronic kidney disease [63]. Accordingly,"/>
 <result pre="be explained by the presence of underlying structural heart disease," exact="stable" post="CAD, and chronic kidney disease [63]. Accordingly, in Western"/>
 <result pre="the presence of underlying structural heart disease, stable CAD, and" exact="chronic" post="kidney disease [63]. Accordingly, in Western countries, the presence"/>
 <result pre="presence of underlying structural heart disease, stable CAD, and chronic" exact="kidney disease" post="[63]. Accordingly, in Western countries, the presence of hs-cTn"/>
 <result pre="of underlying structural heart disease, stable CAD, and chronic kidney" exact="disease" post="[63]. Accordingly, in Western countries, the presence of hs-cTn"/>
 <result pre="as many as 20% of asymptomatic patients with or without" exact="cardiovascular disease" post="presenting for routine outpatient visits [63], and across different"/>
 <result pre="many as 20% of asymptomatic patients with or without cardiovascular" exact="disease" post="presenting for routine outpatient visits [63], and across different"/>
 <result pre="different sub-specialities in patients hospitalized for reasons other than an" exact="acute" post="coronary syndrome [64, 65]. Regardless the underlying reason or"/>
 <result pre="in patients hospitalized for reasons other than an acute coronary" exact="syndrome" post="[64, 65]. Regardless the underlying reason or acuity of"/>
 <result pre="to die acutely during the precipitating event due to their" exact="cardiovascular" post="morbidity [63]. Accordingly, the data from the pandemia in"/>
 <result pre="provide fundamental new information to our interpretation of troponin elevations." exact="Acute" post="myocardial injury related to COVID-19 Based on findings from"/>
 <result pre="related to COVID-19 Based on findings from Corona and Influenza" exact="infections" post="in the past, it has been speculated that acute"/>
 <result pre="Influenza infections in the past, it has been speculated that" exact="acute" post="myocardial injury might be triggered or facilitated in COVID-19"/>
 <result pre="acute myocardial injury might be triggered or facilitated in COVID-19" exact="infection" post="[59, 66]. A previous study on the incidence of"/>
 <result pre="infection [59, 66]. A previous study on the incidence of" exact="myocardial infarction" post="after the outbreak of Influenza infections in Ontario reported"/>
 <result pre="the incidence of myocardial infarction after the outbreak of Influenza" exact="infections" post="in Ontario reported a sixfold higher incidence ratio of"/>
 <result pre="It was hypothesized that an exaggerated inflammatory response mediated by" exact="viral infection" post="with Influenza A or B, respiratory syncytial virus (RSV)"/>
 <result pre="was hypothesized that an exaggerated inflammatory response mediated by viral" exact="infection" post="with Influenza A or B, respiratory syncytial virus (RSV)"/>
 <result pre="response mediated by viral infection with Influenza A or B," exact="respiratory" post="syncytial virus (RSV) or other virus had the potential"/>
 <result pre="virus (RSV) or other virus had the potential to trigger" exact="acute" post="plaque rupture. In addition, anecdotal evidence from sporadic case"/>
 <result pre="anecdotal evidence from sporadic case reports raised the suspicion of" exact="acute" post="myocarditis, although a direct SARS-CoV-2 infiltration of the heart"/>
 <result pre="of acute myocarditis, although a direct SARS-CoV-2 infiltration of the" exact="heart" post="has not been confirmed in the absence of histological"/>
 <result pre="infiltration of the heart has not been confirmed in the" exact="absence of" post="histological confirmation by endocardial biopsy, or by detection of"/>
 <result pre="of histological confirmation by endocardial biopsy, or by detection of" exact="viral" post="genome in myocardial tissue, yet [67]. Previously, a decline"/>
 <result pre="reversible, subclinical diastolic left ventricular impairment that was reported in" exact="acute" post="SARS-CoV-2 infection and was attributed to the cytokine storm"/>
 <result pre="diastolic left ventricular impairment that was reported in acute SARS-CoV-2" exact="infection" post="and was attributed to the cytokine storm syndrome that"/>
 <result pre="acute SARS-CoV-2 infection and was attributed to the cytokine storm" exact="syndrome" post="that is characterized by an uncontrolled and dysfunctional immune"/>
 <result pre="to the cytokine storm syndrome that is characterized by an" exact="uncontrolled" post="and dysfunctional immune response [68]. Finally, cardiotoxic effects of"/>
 <result pre="Finally, cardiotoxic effects of antiviral therapies have been reported [69]." exact="Acute" post="myocardial injury not directly related to COVID-19 Acute myocardial"/>
 <result pre="reported [69]. Acute myocardial injury not directly related to COVID-19" exact="Acute" post="myocardial injury may occur independently from COVID-19 and may"/>
 <result pre="injury may occur independently from COVID-19 and may manifest as" exact="type 1" post="myocardial infarction (STEMI or NSTEMI), type 2 MI in"/>
 <result pre="occur independently from COVID-19 and may manifest as type 1" exact="myocardial infarction" post="(STEMI or NSTEMI), type 2 MI in the absence"/>
 <result pre="may manifest as type 1 myocardial infarction (STEMI or NSTEMI)," exact="type 2" post="MI in the absence of plaque rupture or intracoronary"/>
 <result pre="myocardial infarction (STEMI or NSTEMI), type 2 MI in the" exact="absence of" post="plaque rupture or intracoronary thrombus, or as an acute"/>
 <result pre="absence of plaque rupture or intracoronary thrombus, or as an" exact="acute" post="myocardial injury independent of myocardial ischemia (Fig.Â 4). Cases"/>
 <result pre="intracoronary thrombus, or as an acute myocardial injury independent of" exact="myocardial ischemia" post="(Fig.Â 4). Cases of acute MI on autopsy during"/>
 <result pre="thrombus, or as an acute myocardial injury independent of myocardial" exact="ischemia" post="(Fig.Â 4). Cases of acute MI on autopsy during"/>
 <result pre="myocardial injury independent of myocardial ischemia (Fig.Â 4). Cases of" exact="acute" post="MI on autopsy during hospitalization for COVID-19 have been"/>
 <result pre="of data on the exact prevalence and reasons for an" exact="acute" post="myocardial injury during COVID-19, our interpretation of hs-cTn elevations"/>
 <result pre="has to be discussed on knowledge previously derived from other" exact="acute" post="critical conditions, foremost severe infections causing sepsis or septic"/>
 <result pre="knowledge previously derived from other acute critical conditions, foremost severe" exact="infections" post="causing sepsis or septic shock [70]. In an investigation"/>
 <result pre="other acute critical conditions, foremost severe infections causing sepsis or" exact="septic shock" post="[70]. In an investigation on hs-cTnT in setting of"/>
 <result pre="to 52.6Â ng/L in severe sepsis and 64.1Â ng/L in" exact="septic shock" post="[70]. Likewise, the prevalence of hs-cTnTâ€‰&amp;gt;â€‰ULN increased from 51.6%"/>
 <result pre="hs-cTnTâ€‰&amp;gt;â€‰ULN increased from 51.6% in sepsis to 80.4% % in" exact="septic shock" post="[70]. Very similar to COVID-19, mild elevations of hs-cTnT"/>
 <result pre="index event suggesting a major prognostic role of pre-existing structural" exact="heart" post="disease on long-term outcomes. Similar to SARS-CoV-2 infection, an"/>
 <result pre="event suggesting a major prognostic role of pre-existing structural heart" exact="disease" post="on long-term outcomes. Similar to SARS-CoV-2 infection, an impairment"/>
 <result pre="left ventricular function on echocardiography was common during other severe" exact="infections" post="and there was a clear association between myocardial injury,"/>
 <result pre="demonstrated following rapid atrial pacing, irrespective the presence of inducible" exact="myocardial ischemia" post="[73]. In an experimental human model that utilized the"/>
 <result pre="following rapid atrial pacing, irrespective the presence of inducible myocardial" exact="ischemia" post="[73]. In an experimental human model that utilized the"/>
 <result pre="utilized the trans-cardiac production of lactate for objective evidence of" exact="myocardial ischemia," post="hs-cTnT increased in the absence of CAD and lactate"/>
 <result pre="for objective evidence of myocardial ischemia, hs-cTnT increased in the" exact="absence of" post="CAD and lactate suggesting that tachycardia itself is capable"/>
 <result pre="lactate suggesting that tachycardia itself is capable to induce an" exact="acute" post="myocardial injury. Likewise, administration of catecholamines was found to"/>
 <result pre="that have been related to the release of cTn include" exact="respiratory" post="failure due to severe hypoxemia, sepsis, acute kidney failure,"/>
 <result pre="of cTn include respiratory failure due to severe hypoxemia, sepsis," exact="acute" post="kidney failure, hypertension or hypotension, bradycardia, fever, anemia and"/>
 <result pre="cTn include respiratory failure due to severe hypoxemia, sepsis, acute" exact="kidney failure," post="hypertension or hypotension, bradycardia, fever, anemia and many other"/>
 <result pre="respiratory failure due to severe hypoxemia, sepsis, acute kidney failure," exact="hypertension" post="or hypotension, bradycardia, fever, anemia and many other causes"/>
 <result pre="hypoxemia, sepsis, acute kidney failure, hypertension or hypotension, bradycardia, fever," exact="anemia" post="and many other causes [61, 63]. Fig. 4 Manifestations"/>
 <result pre="and potential pathomechanisms of release of cardiac troponin during COVID-19" exact="infection" post="Practical considerations for patients presenting with suspected or confirmed"/>
 <result pre="Practical considerations for patients presenting with suspected or confirmed COVID-19" exact="infection" post="and suspected Type I Myocardial Infarction (T1MI) Acute MI"/>
 <result pre="patients presenting with suspected or confirmed COVID-19 infection and suspected" exact="Type I" post="Myocardial Infarction (T1MI) Acute MI with or without COVID-19"/>
 <result pre="suspected or confirmed COVID-19 infection and suspected Type I Myocardial" exact="Infarction" post="(T1MI) Acute MI with or without COVID-19 represents a"/>
 <result pre="confirmed COVID-19 infection and suspected Type I Myocardial Infarction (T1MI)" exact="Acute" post="MI with or without COVID-19 represents a life-threatening condition"/>
 <result pre="antiplatelet drugs and monitoring to anticipate complications. However, the enhanced" exact="infectious" post="potency in humans [75] mandates a fundamental risk assessment"/>
 <result pre="to carefully weigh the relative advantages against disadvantages of treating" exact="cardiovascular disease" post="while preventing the risk of SARS-CoV-2 transmission. In patients"/>
 <result pre="carefully weigh the relative advantages against disadvantages of treating cardiovascular" exact="disease" post="while preventing the risk of SARS-CoV-2 transmission. In patients"/>
 <result pre="patients with suspected ACS without ST-segment elevation, or in the" exact="absence of" post="hemodynamic or rhythm instability and when COVID-19 cannot be"/>
 <result pre="CT lung scan while waiting for the PCR result. COVID-19-associated" exact="pneumonia" post="provides a typical picture that is characterized by bilateral"/>
 <result pre="COVID-19-associated pneumonia provides a typical picture that is characterized by" exact="bilateral" post="lung infiltrates, glass ground opacities, consolidation, reticular pattern and"/>
 <result pre="additional information on coronary anatomy and on the presence of" exact="pulmonary embolism" post="since elevations of D-Dimer are not uncommon [7, 60]"/>
 <result pre="60, 76, 77]. Regarding the measurement of cardiac biomarkers, the" exact="American" post="College of Cardiology (ACC) has released statements against the"/>
 <result pre="COVID-19, clinicians are advised to measure cardiac troponin only if" exact="acute" post="myocardial infarction is suspected on clinical grounds [78]. The"/>
 <result pre="clinicians are advised to measure cardiac troponin only if acute" exact="myocardial infarction" post="is suspected on clinical grounds [78]. The European Society"/>
 <result pre="measurement of cardiac troponin T/I concentrations to patients with suspected" exact="Type 1" post="MI, because this infarct type is more likely to"/>
 <result pre="angiography depends on individual estimation of anticipated risk of death," exact="heart" post="failure or other infarct-related complications. Factors that are supposed"/>
 <result pre="high clinical score as recommended in 2015 ESC guidelines [79]." exact="Cardiac" post="troponin values should be interpreted as continuous variables since"/>
 <result pre="likely to benefit most [83]. Hence, patients with NSTEMI at" exact="lower" post="risk should be managed according to local expertise and"/>
 <result pre="the medical staff to an increased risk of contamination [84â€&quot;87]." exact="Heart" post="failure and COVID-19 Is heart failure a risk factor"/>
 <result pre="increased risk of contamination [84â€&quot;87]. Heart failure and COVID-19 Is" exact="heart" post="failure a risk factor for COVID-19? It has long"/>
 <result pre="for COVID-19? It has long been known that patients with" exact="chronic" post="heart failure (CHF) are at increased risk for adverse"/>
 <result pre="COVID-19? It has long been known that patients with chronic" exact="heart" post="failure (CHF) are at increased risk for adverse consequences"/>
 <result pre="adverse consequences of seasonal influenza [88] and other causes of" exact="pneumonia" post="[89]. Conversely, infections and in particular pneumonia are frequent"/>
 <result pre="seasonal influenza [88] and other causes of pneumonia [89]. Conversely," exact="infections" post="and in particular pneumonia are frequent triggers of heart"/>
 <result pre="other causes of pneumonia [89]. Conversely, infections and in particular" exact="pneumonia" post="are frequent triggers of heart failure exacerbations [90]. Of"/>
 <result pre="Conversely, infections and in particular pneumonia are frequent triggers of" exact="heart" post="failure exacerbations [90]. Of note, influenza vaccination decreases mortality"/>
 <result pre="influenza vaccinations may even exceed those of guideline-directed pharmacotherapy [91]." exact="Severe" post="coronavirus infections such as with SARS-CoV-2 have been shown"/>
 <result pre="may even exceed those of guideline-directed pharmacotherapy [91]. Severe coronavirus" exact="infections" post="such as with SARS-CoV-2 have been shown to result"/>
 <result pre="been shown to result in a more severe course of" exact="disease" post="in patients with preexisting cardiovascular disease, including heart failure"/>
 <result pre="a more severe course of disease in patients with preexisting" exact="cardiovascular disease," post="including heart failure [92]. Thus it is not surprising"/>
 <result pre="course of disease in patients with preexisting cardiovascular disease, including" exact="heart" post="failure [92]. Thus it is not surprising that COVID-19"/>
 <result pre="is associated with higher morbidity and mortality in patients with" exact="cardiovascular" post="comorbidities [7, 93]. Yet, likely due to the lower"/>
 <result pre="with cardiovascular comorbidities [7, 93]. Yet, likely due to the" exact="lower" post="prevalence of (known) CHF in China, there is still"/>
 <result pre="lower prevalence of (known) CHF in China, there is still" exact="limited" post="specific information on patients with preexisting heart failure. Nevertheless,"/>
 <result pre="there is still limited specific information on patients with preexisting" exact="heart" post="failure. Nevertheless, some early reports [9] indicate that COVID-19"/>
 <result pre="myocardial injury (s. below) is more frequent in patients with" exact="heart" post="failure and other cardiovascular comorbidities. Myocardial injury in COVID-19"/>
 <result pre="is more frequent in patients with heart failure and other" exact="cardiovascular" post="comorbidities. Myocardial injury in COVID-19 Up to 30% of"/>
 <result pre="a higher likelihood for mechanical ventilation, development of ARDS and" exact="acute" post="kidney failure. Remarkably, 42 of 82 patients with myocardial"/>
 <result pre="higher likelihood for mechanical ventilation, development of ARDS and acute" exact="kidney failure." post="Remarkably, 42 of 82 patients with myocardial injury died"/>
 <result pre="comorbidities as patients with higher troponin levels but without preexisting" exact="cardiovascular" post="or pulmonary disease have a significantly worse prognosis than"/>
 <result pre="patients with higher troponin levels but without preexisting cardiovascular or" exact="pulmonary" post="disease have a significantly worse prognosis than troponin negative"/>
 <result pre="with higher troponin levels but without preexisting cardiovascular or pulmonary" exact="disease" post="have a significantly worse prognosis than troponin negative patients"/>
 <result pre="have a significantly worse prognosis than troponin negative patients with" exact="cardiovascular" post="comorbidities (Guo). It seems likely that myocardial injury is"/>
 <result pre="supported by data that show that COVID-19 non-survivors frequently develop" exact="heart" post="failure (52%) and shock (70%) [7]. Similarly, Ruan et"/>
 <result pre="An obvious reason for an elevated troponin level could be" exact="acute" post="coronary syndrome that obviously may also occur in COVID-19"/>
 <result pre="reason for an elevated troponin level could be acute coronary" exact="syndrome" post="that obviously may also occur in COVID-19 patients, and"/>
 <result pre="in hospitalized COVID-19 patients renders other explanations more likely, including" exact="acute" post="myocarditis due to SARS-CoV-2 or myocardial damage due to"/>
 <result pre="hospitalized COVID-19 patients renders other explanations more likely, including acute" exact="myocarditis" post="due to SARS-CoV-2 or myocardial damage due to proinflammatory"/>
 <result pre="cytokines (â€œcytokine stormâ€�). ACE2 as a potential receptor for Coronavirus" exact="infection" post="(s. above) is highly expressed in cardiomyocytes and in"/>
 <result pre="infection (s. above) is highly expressed in cardiomyocytes and in" exact="vascular" post="pericytes [94]. Thus, it seems plausible that SARS-CoV-2 may"/>
 <result pre="[94]. Thus, it seems plausible that SARS-CoV-2 may directly cause" exact="viral" post="myocarditis with associated cell death and subsequent myocardial injury"/>
 <result pre="Thus, it seems plausible that SARS-CoV-2 may directly cause viral" exact="myocarditis" post="with associated cell death and subsequent myocardial injury as"/>
 <result pre="anecdotal autopsy and endomyocardial biopsy reports describe evidence for an" exact="acute" post="lymphocytic myocarditis [95, 96]. However, the SARS-CoV-2 genome could"/>
 <result pre="and endomyocardial biopsy reports describe evidence for an acute lymphocytic" exact="myocarditis" post="[95, 96]. However, the SARS-CoV-2 genome could not be"/>
 <result pre="Such a â€œcytokine stormâ€� is a well-known [97] while underappreciated" exact="syndrome" post="complicating sepsis in up to 4% of cases [98]."/>
 <result pre="clinical characteristics include multiorgan failure associated with persistent fever and" exact="lymphopenia" post="as well as high levels of ferritin and several"/>
 <result pre="shown to directly impair contractile function of cardiomyocytes [99]. Similarly," exact="lymphopenia" post="and excessively elevated ferritin and interleukin-6 levels have been"/>
 <result pre="increased high sensitive troponin. Specific treatment of the â€œcytokine stormâ€�" exact="and heart" post="failure in COVID-19? Multiple clinical trials are underway which"/>
 <result pre="high sensitive troponin. Specific treatment of the â€œcytokine stormâ€� and" exact="heart" post="failure in COVID-19? Multiple clinical trials are underway which"/>
 <result pre="treatment of the â€œcytokine stormâ€� and heart failure in COVID-19?" exact="Multiple" post="clinical trials are underway which test antiviral agents potentially"/>
 <result pre="several antivirals previously shown to be effective eg in HIV" exact="infections" post="(reviewed in [100]. As myocardial injury is associated with"/>
 <result pre="at the prevention of myocardial damage and/or hyperinflammation. Indeed, the" exact="limited" post="experience with inhibition of the cytokine storm by immunosuppression"/>
 <result pre="cytokines by adsorbent polymer beads (â€œCytosorbâ€�) are sparse. Perspectives Coronavirus" exact="disease" post="2019 (COVID-19) is a pandemic after an outbreak of"/>
 <result pre="disease 2019 (COVID-19) is a pandemic after an outbreak of" exact="pneumonia" post="caused by the novel coronavirus occurred in Wuhan, China."/>
 <result pre="associated with mortality rates between 1 to about 5%. Cardiovascular" exact="disease" post="is an important risk indicator for adverse outcomes and"/>
 <result pre="risk indicator for adverse outcomes and COVID-19 might affect the" exact="cardiovascular" post="system directly. Angiotensin-converting enzyme 2 (ACE2) has been shown"/>
 <result pre="2 (ACE2) has been shown to be a coreceptor for" exact="viral" post="entry downregulating ACE2 with cardiovascular consequences. Cardiovascular disease with"/>
 <result pre="to be a coreceptor for viral entry downregulating ACE2 with" exact="cardiovascular" post="consequences. Cardiovascular disease with dyspnea as a prime symptom"/>
 <result pre="coreceptor for viral entry downregulating ACE2 with cardiovascular consequences. Cardiovascular" exact="disease" post="with dyspnea as a prime symptom like in heart"/>
 <result pre="Cardiovascular disease with dyspnea as a prime symptom like in" exact="heart" post="failure, myocardial ischemia or hypertensive emergency is an important"/>
 <result pre="with dyspnea as a prime symptom like in heart failure," exact="myocardial ischemia" post="or hypertensive emergency is an important differential diagnosis, should"/>
 <result pre="dyspnea as a prime symptom like in heart failure, myocardial" exact="ischemia" post="or hypertensive emergency is an important differential diagnosis, should"/>
 <result pre="a prime symptom like in heart failure, myocardial ischemia or" exact="hypertensive emergency" post="is an important differential diagnosis, should not be ignored"/>
 <result pre="of poor outcome. While there is no evidence for changing" exact="cardiovascular" post="therapy, a complete cardiovascular workup is necessary in COVID-19"/>
 <result pre="While there is no evidence for changing cardiovascular therapy, a" exact="complete" post="cardiovascular workup is necessary in COVID-19 patients and, in"/>
 <result pre="there is no evidence for changing cardiovascular therapy, a complete" exact="cardiovascular" post="workup is necessary in COVID-19 patients and, in particular,"/>
 <result pre="in particular, in patients with cardio-respiratory symptoms and even in" exact="acute" post="respiratory distress syndrome. In turn, cardiopulmonary symptoms should not"/>
 <result pre="particular, in patients with cardio-respiratory symptoms and even in acute" exact="respiratory" post="distress syndrome. In turn, cardiopulmonary symptoms should not distract"/>
 <result pre="symptoms should not distract physicians from an unbiased work-up of" exact="cardiovascular" post="conditions as these patients could suffer from life-threatening cardiovascular"/>
 <result pre="of cardiovascular conditions as these patients could suffer from life-threatening" exact="cardiovascular" post="conditions in the absence of COVID-19. Healthcare providers in"/>
 <result pre="these patients could suffer from life-threatening cardiovascular conditions in the" exact="absence of" post="COVID-19. Healthcare providers in high, middle and low income"/>
 <result pre="income countries need to be aware of the importance of" exact="cardiovascular disease" post="in patients with SARS and COVID-19 infections by providing"/>
 <result pre="countries need to be aware of the importance of cardiovascular" exact="disease" post="in patients with SARS and COVID-19 infections by providing"/>
 <result pre="importance of cardiovascular disease in patients with SARS and COVID-19" exact="infections" post="by providing optimal cardiovascular care. For the German Cardiac"/>
 <result pre="in patients with SARS and COVID-19 infections by providing optimal" exact="cardiovascular" post="care. For the German Cardiac Society: Michael BÃ¶hm, Norbert"/>
 <result pre="COVID-19 infections by providing optimal cardiovascular care. For the German" exact="Cardiac" post="Society: Michael BÃ¶hm, Norbert Frey, Evangelos Giannitsis and Andreas"/>
 <result pre="Frey, Evangelos Giannitsis and Andreas M. Zeiher. For the World" exact="Heart" post="Federation: Michael BÃ¶hm and Karen Sliwa. References References 1.CucinottaDVanelliMWHO"/>
 <result pre="J Surg202010.1002/bjs.1162732363596 3.WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="a report of 72â€¯314 cases from the chinese center for" exact="disease" post="control and preventionJAMA202010.1001/jama.2020.264832275295 4.ChannappanavarRPerlmanSPathogenic human coronavirus infections: causes and"/>
 <result pre="complicated with fulminant myocarditis: a case report and insightsInfection202010.1007/s15010-020-01424-532277408 6.KwongJCSchwartzKLCampitelliMAChungHCrowcroftNSKarnauchowTKatzKKoDTMcGeerAJMcNallyDRichardsonDCRosellaLCSimorASmiejaMZahariadisGGubbayJBAcute" exact="myocardial infarction" post="after laboratory-confirmed influenza infectionN Engl J Med201837834535329365305 7.ZhouFYuTDuRFanGLiuYLiuZXiangJWangYSongBGuXGuanLWeiYLiHWuXXuJTuSZhangYChenHCaoBClinical course"/>
 <result pre="J Med201837834535329365305 7.ZhouFYuTDuRFanGLiuYLiuZXiangJWangYSongBGuXGuanLWeiYLiHWuXXuJTuSZhangYChenHCaoBClinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="studyLancet20203951054106210.1016/S0140-6736(20)30566-332171076 8.GuoTFanYChenMWuXZhangLHeTWangHWanJWangXLuZCardiovascular implications of fatal outcomes of patients with Coronavirus" exact="Disease" post="2019 (COVID-19)JAMA Cardiol202010.1001/jamacardio.2020.101732293644 9.ShiSQinMShenBCaiYLiuTYangFGongWLiuXLiangJZhaoQHuangHYangBHuangCAssociation of cardiac injury with mortality"/>
 <result pre="Infected Patients (LEOSS) registry protocols. https://leoss.net/ 13.Corrales-MedinaVFAlvarezKNWeissfeldLAAngusDCChirinosJAChangCCNewmanALoehrLFolsomARElkindMSLylesMFKronmalRAYendeSAssociation between hospitalization for" exact="pneumonia" post="and subsequent risk of cardiovascular diseaseJAMA201531326427425602997 14.ZillaPBolmanRMYacoubMHBeyersdorfFSliwaKZÃ¼hlkeLHigginsRSDMayosiBCarpentierAWilliamsDThe Cape Town"/>
 <result pre="https://leoss.net/ 13.Corrales-MedinaVFAlvarezKNWeissfeldLAAngusDCChirinosJAChangCCNewmanALoehrLFolsomARElkindMSLylesMFKronmalRAYendeSAssociation between hospitalization for pneumonia and subsequent risk of" exact="cardiovascular" post="diseaseJAMA201531326427425602997 14.ZillaPBolmanRMYacoubMHBeyersdorfFSliwaKZÃ¼hlkeLHigginsRSDMayosiBCarpentierAWilliamsDThe Cape Town declaration on access to cardiac"/>
 <result pre="surgery in the developing worldJ Thorac Cardiovasc Surg20181562206220930082076 15.LwabiPNamuyongaJLubegaSOketchoMMwambuTSebattaEOkelloEOmaginoJSliwaKThe Uganda" exact="Heart" post="AssociationEur Heart J2019402396239731539909 16.SliwaKNtusiNBattling cardiovascular diseases in a perfect"/>
 <result pre="the developing worldJ Thorac Cardiovasc Surg20181562206220930082076 15.LwabiPNamuyongaJLubegaSOketchoMMwambuTSebattaEOkelloEOmaginoJSliwaKThe Uganda Heart AssociationEur" exact="Heart" post="J2019402396239731539909 16.SliwaKNtusiNBattling cardiovascular diseases in a perfect stormCirculation20191391658166030933612 17.ThienemannFPintoFGrobbeeDEBoehmMBazarganiNGeJSliwaKWorld"/>
 <result pre="Thorac Cardiovasc Surg20181562206220930082076 15.LwabiPNamuyongaJLubegaSOketchoMMwambuTSebattaEOkelloEOmaginoJSliwaKThe Uganda Heart AssociationEur Heart J2019402396239731539909 16.SliwaKNtusiNBattling" exact="cardiovascular" post="diseases in a perfect stormCirculation20191391658166030933612 17.ThienemannFPintoFGrobbeeDEBoehmMBazarganiNGeJSliwaKWorld heart federation briefing"/>
 <result pre="Heart J2019402396239731539909 16.SliwaKNtusiNBattling cardiovascular diseases in a perfect stormCirculation20191391658166030933612 17.ThienemannFPintoFGrobbeeDEBoehmMBazarganiNGeJSliwaKWorld" exact="heart" post="federation briefing on prevention: coronavirus disease 2019 (COVID-19) in"/>
 <result pre="a perfect stormCirculation20191391658166030933612 17.ThienemannFPintoFGrobbeeDEBoehmMBazarganiNGeJSliwaKWorld heart federation briefing on prevention: coronavirus" exact="disease" post="2019 (COVID-19) in low-income countriesGlob Heart20201513110.5334/gh.778 18.WilliamsBManciaGSpieringWAgabiti RoseiEAziziMBurnierMClementDLCocaAde SimoneGDominiczakAKahanTMahfoudFRedonJRuilopeLZanchettiAKerinsMKjeldsenSEKreutzRLaurentSLipGYHMcManusRNarkiewiczKRuschitzkaFSchmiederREShlyakhtoETsioufisCAboyansVDesormaisIcollab:"/>
 <result pre="Document Group2018 ESC/ESH Guidelines for the management of arterial hypertensionEur" exact="Heart" post="J2018393021310430165516 19.WheltonPKCareyRMAronowWSCaseyDEJrCollinsKJDennison HimmelfarbCDePalmaSMGiddingSJamersonKAJonesDWMacLaughlinEJMuntnerPOvbiageleBSmithSCJrSpencerCCStaffordRSTalerSJThomasRJWilliamsKASrWilliamsonJDWrightJTJr2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection,"/>
 <result pre="ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of" exact="high blood pressure" post="in adults: a report of the American College of"/>
 <result pre="of high blood pressure in adults: a report of the" exact="American" post="College of Cardiology/American Heart Association task force on clinical"/>
 <result pre="in adults: a report of the American College of Cardiology/American" exact="Heart" post="Association task force on clinical practice guidelinesCirculation2018138e426e48330354655 20.TipnisSRHooperNMHydeRKarranEChristieGTurnerAJA human"/>
 <result pre="of an intracardiac renin-angiotensin systemAnnu Rev Physiol1992542272411562174 22.KaschinaENamsolleckPUngerTAT2 receptors in" exact="cardiovascular" post="and renal diseasePharmacol Res2017125394728694144 23.DonoghueMHsiehFBaronasEGodboutKGosselinMStaglianoNDonovanMWoolfBRobisonKJeyaseelanRBreitbartREActonSA novel angiotensin-converting enzyme-related carboxypeptidase"/>
 <result pre="factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)J Biol Chem2005280301133011915983030 29.WallsACParkYJTortoriciMAWallAMcGuireATVeeslerDStructure,"/>
 <result pre="injuryNat Med20051187587916007097 33.GuHXieZLiTZhangSLaiCZhuPWangKHanLDuanYZhaoZYangXXingLZhangPWangZLiRYuJJWangXYangPAngiotensin-converting enzyme 2 inhibits lung injury induced by" exact="respiratory" post="syncytial virusSci Rep201661984026813885 34.ZouZYanYShuYGaoRSunYLiXJuXLiangZLiuQZhaoYGuoFBaiTHanZZhuJZhouHHuangFLiCLuHLiNLiDJinNPenningerJMJiangCAngiotensin-converting enzyme 2 protects from lethal"/>
 <result pre="respiratory syncytial virusSci Rep201661984026813885 34.ZouZYanYShuYGaoRSunYLiXJuXLiangZLiuQZhaoYGuoFBaiTHanZZhuJZhouHHuangFLiCLuHLiNLiDJinNPenningerJMJiangCAngiotensin-converting enzyme 2 protects from lethal" exact="avian influenza" post="A H5N1 infectionsNat Commun20145359424800825 35.JiaHPulmonary angiotensin-converting enzyme 2 (ACE2)"/>
 <result pre="and inflammatory lung diseaseShock20164623924827082314 36.ImaiYKubaKRaoSHuanYGuoFGuanBYangPSaraoRWadaTLeong-PoiHCrackowerMAFukamizuAHuiCCHeinLUhligSSlutskyASJiangCPenningerJMAngiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature200543611211616001071 37.KhanABenthinCZenoBAlbertsonTEBoydJChristieJDHallRPoirierGRoncoJJTidswellMHardesKPowleyWMWrightTJSiedererSKFairmanDALipsonDABayliffeAILazaarALA pilot clinical trial of recombinant human"/>
 <result pre="pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in" exact="acute" post="respiratory distress syndromeCrit Care20172123428877748 38.HammingIvan GoorHTurnerAJRushworthCAMichaudAACorvolPNavisGDifferential regulation of renal"/>
 <result pre="clinical trial of recombinant human angiotensin-converting enzyme 2 in acute" exact="respiratory" post="distress syndromeCrit Care20172123428877748 38.HammingIvan GoorHTurnerAJRushworthCAMichaudAACorvolPNavisGDifferential regulation of renal angiotensin-converting"/>
 <result pre="downregulation of Angiotensin-converting enzyme 2 in the late phase of" exact="ventricular dysfunction" post="in myocardial infarcted ratHypertension20064857257816908757 40.FerrarioCMJessupJChappellMCAverillDBBrosnihanKBTallantEADizDIGallagherPEEffect of angiotensin-converting enzyme inhibition"/>
 <result pre="cardiac angiotensin-converting enzyme 2Circulation20051112605261015897343 41.EpelmanSShresthaKTroughtonRWFrancisGSSenSKleinALTangWHSoluble angiotensin-converting enzyme 2 in human" exact="heart" post="failure: relation with myocardial function and clinical outcomesJ Card"/>
 <result pre="increased plasma angiotensin converting enzyme 2 activity is associated with" exact="atrial fibrillation" post="and more advanced left atrial structural remodellingEuropace2017191280128727738071 43.HemnesARRathinasabapathyAAustinEABrittainELCarrierEJChenXFesselJPFikeCDFongPFortuneNGersztenREJohnsonJAKaplowitzMNewmanJHPianaRPughMERiceTWRobbinsIMWheelerLYuCLoydJEWestJA potential"/>
 <result pre="plasma angiotensin converting enzyme 2 activity is associated with atrial" exact="fibrillation" post="and more advanced left atrial structural remodellingEuropace2017191280128727738071 43.HemnesARRathinasabapathyAAustinEABrittainELCarrierEJChenXFesselJPFikeCDFongPFortuneNGersztenREJohnsonJAKaplowitzMNewmanJHPianaRPughMERiceTWRobbinsIMWheelerLYuCLoydJEWestJA potential"/>
 <result pre="43.HemnesARRathinasabapathyAAustinEABrittainELCarrierEJChenXFesselJPFikeCDFongPFortuneNGersztenREJohnsonJAKaplowitzMNewmanJHPianaRPughMERiceTWRobbinsIMWheelerLYuCLoydJEWestJA potential therapeutic role for angiotensin-converting enzyme 2 in human" exact="pulmonary" post="arterial hypertensionEur Respir J201810.1183/13993003.02638-201729903860 44.YangZJLiuJGeJPChenLZhaoZGYangWYcollab: China National Diabetes and"/>
 <result pre="in human pulmonary arterial hypertensionEur Respir J201810.1183/13993003.02638-201729903860 44.YangZJLiuJGeJPChenLZhaoZGYangWYcollab: China National" exact="Diabetes" post="and Metabolic Disorders Study GroupPrevalence of cardiovascular disease risk"/>
 <result pre="arterial hypertensionEur Respir J201810.1183/13993003.02638-201729903860 44.YangZJLiuJGeJPChenLZhaoZGYangWYcollab: China National Diabetes and Metabolic" exact="Disorders" post="Study GroupPrevalence of cardiovascular disease risk factor in the"/>
 <result pre="44.YangZJLiuJGeJPChenLZhaoZGYangWYcollab: China National Diabetes and Metabolic Disorders Study GroupPrevalence of" exact="cardiovascular disease" post="risk factor in the Chinese population: the 2007â€&quot;2008 China"/>
 <result pre="China National Diabetes and Metabolic Disorders Study GroupPrevalence of cardiovascular" exact="disease" post="risk factor in the Chinese population: the 2007â€&quot;2008 China"/>
 <result pre="risk factor in the Chinese population: the 2007â€&quot;2008 China National" exact="Diabetes" post="and Metabolic Disorders StudyEur Heart J20123321322021719451 45.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYZhaoYLiYWangXPengZClinical characteristics of"/>
 <result pre="the Chinese population: the 2007â€&quot;2008 China National Diabetes and Metabolic" exact="Disorders" post="StudyEur Heart J20123321322021719451 45.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYZhaoYLiYWangXPengZClinical characteristics of 138 hospitalized patients"/>
 <result pre="population: the 2007â€&quot;2008 China National Diabetes and Metabolic Disorders StudyEur" exact="Heart" post="J20123321322021719451 45.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYZhaoYLiYWangXPengZClinical characteristics of 138 hospitalized patients with 2019"/>
 <result pre="45.WangDHuBHuCZhuFLiuXZhangJWangBXiangHChengZXiongYZhaoYLiYWangXPengZClinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA202010.1001/jama.2020.158532315061 46.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with acute respiratory"/>
 <result pre="novel coronavirus-infected pneumonia in Wuhan, ChinaJAMA202010.1001/jama.2020.158532315061 46.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
 <result pre="coronavirus-infected pneumonia in Wuhan, ChinaJAMA202010.1001/jama.2020.158532315061 46.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="in Wuhan, ChinaJAMA202010.1001/jama.2020.158532315061 46.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern Med202010.1001/jamainternmed.2020.099432338717 47.GrasselliGZangrilloAZanellaAAntonelliMCabriniLCastelliACeredaDColuccelloAFotiGFumagalliRIottiGLatronicoNLoriniLMerlerSNataliniGPiattiARanieriMVScandroglioAMStortiECecconiMPesentiAcollab: COVID-19"/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, ChinaJAMA Intern Med202010.1001/jamainternmed.2020.099432338717 47.GrasselliGZangrilloAZanellaAAntonelliMCabriniLCastelliACeredaDColuccelloAFotiGFumagalliRIottiGLatronicoNLoriniLMerlerSNataliniGPiattiARanieriMVScandroglioAMStortiECecconiMPesentiAcollab: COVID-19 Lombardy ICU"/>
 <result pre="admitted to ICUs of the Lombardy region, ItalyJAMA202010.1001/jama.2020.539432250385 48.WangZChenZZhangLWangXHaoGZhangZShaoLTianYDongYZhengCWangJZhuMWeintraubWSGaoRcollab: China" exact="Hypertension" post="Survey InvestigatorsStatus of hypertension in China: Results from the"/>
 <result pre="the Lombardy region, ItalyJAMA202010.1001/jama.2020.539432250385 48.WangZChenZZhangLWangXHaoGZhangZShaoLTianYDongYZhengCWangJZhuMWeintraubWSGaoRcollab: China Hypertension Survey InvestigatorsStatus of" exact="hypertension" post="in China: Results from the China hypertension survey, 2012â€&quot;2015Circulation20181372344235629449338"/>
 <result pre="Survey InvestigatorsStatus of hypertension in China: Results from the China" exact="hypertension" post="survey, 2012â€&quot;2015Circulation20181372344235629449338 49.LiuLScollab: Writing Group of 2010 Chinese Guidelines"/>
 <result pre="20192019Berlin, HeidelbergSpringer Berlin Heidelberg 51.LuJLuYWangXLiXLindermanGCWuCChengXMuLZhangHLiuJSuMZhaoHSpatzESSpertusJAMasoudiFAKrumholzHMJiangLPrevalence, awareness, treatment, and control of" exact="hypertension" post="in China: data from 1Â·7 million adults in a"/>
 <result pre="of the renin-angiotensin system be withdrawn in patients with COVID-19?Eur" exact="Heart" post="J202010.1093/eurheartj/ehaa23532432723 53.BavishiCMaddoxTMMesserliFHCoronavirus Disease 2019 (COVID-19) infection and renin angiotensin"/>
 <result pre="system be withdrawn in patients with COVID-19?Eur Heart J202010.1093/eurheartj/ehaa23532432723 53.BavishiCMaddoxTMMesserliFHCoronavirus" exact="Disease" post="2019 (COVID-19) infection and renin angiotensin system blockersJAMA Cardiol202010.1001/jamacardio.2020.128232242890"/>
 <result pre="in patients with COVID-19?Eur Heart J202010.1093/eurheartj/ehaa23532432723 53.BavishiCMaddoxTMMesserliFHCoronavirus Disease 2019 (COVID-19)" exact="infection" post="and renin angiotensin system blockersJAMA Cardiol202010.1001/jamacardio.2020.128232242890 54.PatelABVermaACOVID-19 and angiotensin-converting"/>
 <result pre="angiotensin receptor blockers: what is the evidence?JAMA202010.1001/jama.2020.481232432681 55.FangLKarakiulakisGRothMAre patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="blockers: what is the evidence?JAMA202010.1001/jama.2020.481232432681 55.FangLKarakiulakisGRothMAre patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir Med20208e2110.1016/S2213-2600(20)30116-832171062 56.SommersteinRGrÃ¤niCPreventing"/>
 <result pre="be harmful in the COVID-19 pandemic?J Hypertens20203878178232195824 59.XiongTYRedwoodSPrendergastBChenMCoronaviruses and the" exact="cardiovascular" post="system: acute and long-term implicationsEur Heart J202010.1093/eurheartj/ehaa23132186331 60.ChenNZhouMDongXet al.Epidemiological"/>
 <result pre="in the COVID-19 pandemic?J Hypertens20203878178232195824 59.XiongTYRedwoodSPrendergastBChenMCoronaviruses and the cardiovascular system:" exact="acute" post="and long-term implicationsEur Heart J202010.1093/eurheartj/ehaa23132186331 60.ChenNZhouMDongXet al.Epidemiological and clinical"/>
 <result pre="Hypertens20203878178232195824 59.XiongTYRedwoodSPrendergastBChenMCoronaviruses and the cardiovascular system: acute and long-term implicationsEur" exact="Heart" post="J202010.1093/eurheartj/ehaa23132186331 60.ChenNZhouMDongXet al.Epidemiological and clinical characteristics of 99 cases"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet20203951022350751310.1016/S0140-6736(20)30211-732007143 61.ThygesenKAlpertJSJaffeASet al.Fourth universal"/>
 <result pre="Wuhan, China: a descriptive studyLancet20203951022350751310.1016/S0140-6736(20)30211-732007143 61.ThygesenKAlpertJSJaffeASet al.Fourth universal definition of" exact="myocardial infarction" post="(2018)Eur Heart J20194023726910.1093/eurheartj/ehy462 62.MuellerMBienerMVafaieMet al.Absolute and relative kinetic changes"/>
 <result pre="descriptive studyLancet20203951022350751310.1016/S0140-6736(20)30211-732007143 61.ThygesenKAlpertJSJaffeASet al.Fourth universal definition of myocardial infarction (2018)Eur" exact="Heart" post="J20194023726910.1093/eurheartj/ehy462 62.MuellerMBienerMVafaieMet al.Absolute and relative kinetic changes of high-sensitivity"/>
 <result pre="and relative kinetic changes of high-sensitivity cardiac troponin T in" exact="acute" post="coronary syndrome and in patients with increased troponin in"/>
 <result pre="kinetic changes of high-sensitivity cardiac troponin T in acute coronary" exact="syndrome" post="and in patients with increased troponin in the absence"/>
 <result pre="coronary syndrome and in patients with increased troponin in the" exact="absence of" post="acute coronary syndromeClin Chem201258120921822134520 63.GiannitsisEKatusHACardiac troponin level elevations not"/>
 <result pre="and in patients with increased troponin in the absence of" exact="acute" post="coronary syndromeClin Chem201258120921822134520 63.GiannitsisEKatusHACardiac troponin level elevations not related"/>
 <result pre="coronary syndromeClin Chem201258120921822134520 63.GiannitsisEKatusHACardiac troponin level elevations not related to" exact="acute" post="coronary syndromesNat Rev Cardiol2013101162363410.1038/nrcardio.2013.12923979214 64.McFallsEOLarsenGJohnsonGRet al.Outcomes of hospitalized patients"/>
 <result pre="Rev Cardiol2013101162363410.1038/nrcardio.2013.12923979214 64.McFallsEOLarsenGJohnsonGRet al.Outcomes of hospitalized patients with non-acute coronary" exact="syndrome" post="and elevated cardiac troponin levelAm J Med2011124763063510.1016/j.amjmed.2011.02.02421601821 65.IversenKKÃ¸berLGÃ¸tzeJPet al.Troponin"/>
 <result pre="marker of mortality in hospitalized patientsInt J Cardiol2013168281882423117016 66.KwongJCSchwartzKLCampitelliMAet al.Acute" exact="myocardial infarction" post="after laboratory-confirmed influenza infectionN Engl J Med2018378434535310.1056/NEJMoa170209029365305 67.InciardiRMLupiLZacconeGItaliaLRaffoMTomasoniDCaniDSCeriniMFarinaDGavazziEMaroldiRAdamoMAmmiratiESinagraGLombardiCMMetraMCardiac involvement"/>
 <result pre="Engl J Med2018378434535310.1056/NEJMoa170209029365305 67.InciardiRMLupiLZacconeGItaliaLRaffoMTomasoniDCaniDSCeriniMFarinaDGavazziEMaroldiRAdamoMAmmiratiESinagraGLombardiCMMetraMCardiac involvement in a patient with Coronavirus" exact="Disease" post="2019 (COVID-19)JAMA Cardiol202010.1001/jamacardio.2020.109632219357 68.LiSSChengCWFuCLet al.Left ventricular performance in patients"/>
 <result pre="(COVID-19)JAMA Cardiol202010.1001/jamacardio.2020.109632219357 68.LiSSChengCWFuCLet al.Left ventricular performance in patients with severe" exact="acute" post="respiratory syndrome: a 30-day echocardiographic follow-up studyCirculation2003108151798180310.1161/01.CIR.0000094737.21775.3214504188 69.VargaZVFerdinandyPLiaudetLPacherPDrug-induced mitochondrial"/>
 <result pre="Cardiol202010.1001/jamacardio.2020.109632219357 68.LiSSChengCWFuCLet al.Left ventricular performance in patients with severe acute" exact="respiratory" post="syndrome: a 30-day echocardiographic follow-up studyCirculation2003108151798180310.1161/01.CIR.0000094737.21775.3214504188 69.VargaZVFerdinandyPLiaudetLPacherPDrug-induced mitochondrial dysfunction"/>
 <result pre="echocardiographic follow-up studyCirculation2003108151798180310.1161/01.CIR.0000094737.21775.3214504188 69.VargaZVFerdinandyPLiaudetLPacherPDrug-induced mitochondrial dysfunction and cardiotoxicityAm J Physiol" exact="Heart" post="Circ Physiol20153099H1453H146710.1152/ajpheart.00554.201526386112 70.WilhelmJHettwerSSchuermannMet al.Elevated troponin in septic patients in"/>
 <result pre="diastolic dysfunction and right ventricular dilatation*Crit Care Med201442479080010.1097/CCM.000000000000010724365861 73.TurerATAddoTAMartinJLet al.Myocardial" exact="ischemia" post="induced by rapid atrial pacing causes troponin T release"/>
 <result pre="effective reproduction number of SARS-CoV-2J Med Virol202010.1002/jmv.2572332427358 76.AiTYangZHouHet al.Correlation of" exact="chest" post="CT and RT-PCR testing in Coronavirus Disease 2019 (COVID-19)"/>
 <result pre="76.AiTYangZHouHet al.Correlation of chest CT and RT-PCR testing in Coronavirus" exact="Disease" post="2019 (COVID-19) in China: a report of 1014 casesRadiology202010.1148/radiol.202020064232101510"/>
 <result pre="Haemost202018484484710.1111/jth.1476832073213 78.https://www.acc.org/latest-incardiology/articles-/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 79.RoffiMPatronoCColletJPet al.2015 ESC Guidelines for the management of" exact="acute" post="coronary syndromes in patients presenting without persistent ST-segment elevation:"/>
 <result pre="without persistent ST-segment elevation: Task Force for the Management of" exact="Acute Coronary Syndromes" post="in Patients Presenting without Persistent ST-Segment Elevation of the"/>
 <result pre="persistent ST-segment elevation: Task Force for the Management of Acute" exact="Coronary Syndromes" post="in Patients Presenting without Persistent ST-Segment Elevation of the"/>
 <result pre="ST-segment elevation: Task Force for the Management of Acute Coronary" exact="Syndromes" post="in Patients Presenting without Persistent ST-Segment Elevation of the"/>
 <result pre="Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)Eur" exact="Heart" post="J201637326731526320110 80.StoyanovKMHundHBienerMet al.RAPID-CPU: a prospective study on implementation of"/>
 <result pre="algorithm and safety of discharge after rule-out of myocardial infarctionEur" exact="Heart" post="J Acute Cardiovasc Care202091395131298551 81.TwerenboldRCostabelJPNestelbergerTet al.Outcome of applying the"/>
 <result pre="safety of discharge after rule-out of myocardial infarctionEur Heart J" exact="Acute" post="Cardiovasc Care202091395131298551 81.TwerenboldRCostabelJPNestelbergerTet al.Outcome of applying the ESC 0/1-hour"/>
 <result pre="new high-sensitivity cardiac troponin T assay improves risk assessment in" exact="acute" post="coronary syndromesAm Heart J2010160222422910.1016/j.ahj.2010.05.02320691825 83.JobsAMehtaSRMontalescotGet al.Optimal timing of an"/>
 <result pre="troponin T assay improves risk assessment in acute coronary syndromesAm" exact="Heart" post="J2010160222422910.1016/j.ahj.2010.05.02320691825 83.JobsAMehtaSRMontalescotGet al.Optimal timing of an invasive strategy in"/>
 <result pre="al.Optimal timing of an invasive strategy in patients with non-ST-elevation" exact="acute" post="coronary syndrome: a meta-analysis of randomised trialsLancet20173901009673774610.1016/S0140-6736(17)31490-328778541 84.(2020) ACC"/>
 <result pre="Patients, Health Care Workers, and Health Systems During the Coronavirus" exact="Disease" post="2019 (COVID-19) PandemicJ Am Coll Cardiol202010.1016/j.jacc.2020.03.03132311448 86.https://dgk.org/daten/echo-anleitung-in-zeiten-von-covid-19_final-1.pdf 87.American College"/>
 <result pre="May 2020 88.AlonDSteinGYKorenfeldRFuchsSPredictors and outcomes of infection-related hospital admissions of" exact="heart" post="failure patientsPLoS ONE20138e7247610.1371/journal.pone.007247624009684 89.SandovalCWalterSDKruegerPSmiejaMSmithAYusufSLoebMBRisk of hospitalization during influenza season"/>
 <result pre="during influenza season among a cohort of patients with congestive" exact="heart" post="failureEpidemiol Infect200713557458210.1017/S095026880600714X16938140 90.KytÃ¶maaSHegdeSClaggettBUdellJARosamondWTemteJNicholKWrightJDSolomonSDVardenyOAssociation of influenza-like illness activity with hospitalizations"/>
 <result pre="failureEpidemiol Infect200713557458210.1017/S095026880600714X16938140 90.KytÃ¶maaSHegdeSClaggettBUdellJARosamondWTemteJNicholKWrightJDSolomonSDVardenyOAssociation of influenza-like illness activity with hospitalizations for" exact="heart" post="failure: the atherosclerosis risk in communities studyJAMA Cardiol20194436336910.1001/jamacardio.2019.054930916717 91.ModinDJorgensenMEGislasonGJensenJSKoberLClaggettBHegdeSMSolomonSDTorp-PedersenCBiering-SÃ¸rensenTInfluenza"/>
 <result pre="of influenza-like illness activity with hospitalizations for heart failure: the" exact="atherosclerosis" post="risk in communities studyJAMA Cardiol20194436336910.1001/jamacardio.2019.054930916717 91.ModinDJorgensenMEGislasonGJensenJSKoberLClaggettBHegdeSMSolomonSDTorp-PedersenCBiering-SÃ¸rensenTInfluenza vaccine in heart"/>
 <result pre="the atherosclerosis risk in communities studyJAMA Cardiol20194436336910.1001/jamacardio.2019.054930916717 91.ModinDJorgensenMEGislasonGJensenJSKoberLClaggettBHegdeSMSolomonSDTorp-PedersenCBiering-SÃ¸rensenTInfluenza vaccine in" exact="heart" post="failure: cumulative number of vaccinations, frequency, timing, and survival:"/>
 <result pre="risk factors for adverse clinical outcomes in adults with severe" exact="acute" post="respiratory syndrome (SARS)Thorax200358868668912885985 93.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of cardiovascular metabolic"/>
 <result pre="factors for adverse clinical outcomes in adults with severe acute" exact="respiratory" post="syndrome (SARS)Thorax200358868668912885985 93.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of cardiovascular metabolic diseases"/>
 <result pre="for adverse clinical outcomes in adults with severe acute respiratory" exact="syndrome" post="(SARS)Thorax200358868668912885985 93.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of cardiovascular metabolic diseases on"/>
 <result pre="with severe acute respiratory syndrome (SARS)Thorax200358868668912885985 93.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of" exact="cardiovascular" post="metabolic diseases on COVID-19 in ChinaClin Res Cardiol202010953153832161990 94.ChenLHaoGThe"/>
 <result pre="severe acute respiratory syndrome (SARS)Thorax200358868668912885985 93.LiBYangJZhaoFZhiLWangXLiuLBiZZhaoYPrevalence and impact of cardiovascular" exact="metabolic diseases" post="on COVID-19 in ChinaClin Res Cardiol202010953153832161990 94.ChenLHaoGThe role of"/>
 <result pre="94.ChenLHaoGThe role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and" exact="cardiovascular" post="diseaseCardiovasc Res202010.1093/cvr/cvaa09332267921 95.SalaSPerettoGGramegnaMPalmisanoAVillatoreAVignaleDDe CobelliFTresoldiMCappellettiAMBassoCGodinoCEspositoAAcute myocarditis presenting as a reverse"/>
 <result pre="2 in coronaviruses/influenza viruses and cardiovascular diseaseCardiovasc Res202010.1093/cvr/cvaa09332267921 95.SalaSPerettoGGramegnaMPalmisanoAVillatoreAVignaleDDe CobelliFTresoldiMCappellettiAMBassoCGodinoCEspositoAAcute" exact="myocarditis" post="presenting as a reverse Tako-Tsubo syndrome in a patient"/>
 <result pre="diseaseCardiovasc Res202010.1093/cvr/cvaa09332267921 95.SalaSPerettoGGramegnaMPalmisanoAVillatoreAVignaleDDe CobelliFTresoldiMCappellettiAMBassoCGodinoCEspositoAAcute myocarditis presenting as a reverse Tako-Tsubo" exact="syndrome" post="in a patient with SARS-CoV-2 respiratory infectionEur Heart J202010.1093/eurheartj/ehaa28632363406"/>
 <result pre="as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2" exact="respiratory" post="infectionEur Heart J202010.1093/eurheartj/ehaa28632363406 96.YaoXHLiTYHeZCet al.A pathological report of three"/>
 <result pre="reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infectionEur" exact="Heart" post="J202010.1093/eurheartj/ehaa28632363406 96.YaoXHLiTYHeZCet al.A pathological report of three covid-19 cases"/>
 <result pre="of meningococcal septic shockLancet2004363940420320914738793 100.MadjidMSafavi-NaeiniPSolomonSDVardenyOPotential effects of coronaviruses on the" exact="cardiovascular" post="system: a reviewJAMA Cardiol202010.1001/jamacardio.2020.128632219363 101.ShakooryBCarcilloJAChathamWWAmdurRLZhaoHDinarelloCACronRQOpalSMInterleukin-1 receptor blockade is associated"/>
</results>
